ArticleBMC research notes2025
A possible role of urinary genotoxic Escherichia coli in prostate cancer in Nigerian patients.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Unraveling the microbial landscape in prostate cancer: pathogenesis to therapy.NPJ biofilms and microbiomes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInfection and inflammation are potential initiating factors for the development and progression of prostate cancer. This study investigated the presence of bacterial genotoxins; colibactin (clb) and cytolethal distending toxin (cdt) in Escherichia coli isolated from urine samples of individuals diagnosed with prostate cancer as well as those with benign prostatic hyperplasia. E. coli was isolated from urine samples from prostate cancer patients (cases, n = 30) and men with benign prostate hyperplasia (controls, n = 40). The presence of colibactin (clb) and cytolethal distending toxin (cdt) genes was evaluated in E. coli isolates using polymerase chain reaction.
resultsThe frequency of E. coli was 36.0% of prostate cancer patients and 30.0% of controls, respectively (p = 0.557). Furthermore, there was a higher occurrence of the clb gene in cases compared to controls (36.4% vs. 8.3%). Cytolethal distending toxin (cdt) gene was absent in all isolates examined. The analysis revealed no significant relationship between the selected genotoxins and prostate cancer (p = 0.104). The Gleason grade of the cancer was not a major determinant in the occurrence of clb within the cancer cases. The present study is the first report investigating bacterial genotoxins in urine samples of Nigerian prostate cancer patients. Our findings showed no association between bacterial genotoxins and prostate cancer. Additional investigations are warranted to further investigate the role of bacterial genotoxins in prostate cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.